Tilray | TRLY - Gross Profit On Sales

Stock Price
1.53
Daily Change
-0.11 -6.71%
Monthly
20.47%
Yearly
-34.05%
Q3 Forecast
1.63

Tilray reported $61.22M in Gross Profit on Sales for its fiscal quarter ending in November of 2024.



Financials
Stock Price USD
Assets USD 4.19B
Cash and Equivalent USD 189.7M
Cost of Sales USD 149.73M
Current Assets USD 707.34M
Current Liabilities USD 278.52M
Debt USD 351.72M
EBIT USD -42.22M
EBITDA USD -101K
Employees USD 2.65K
EPS Earnings Per Share USD -1.78
Equity Capital and Reserves USD 3.47B
Gross Profit on Sales USD 61.22M
Interest Expense on Debt USD 7.77M
Interest Income USD 12.83M
Loan Capital USD 316.63M
Market Capitalization USD 1.18B
Net Income USD -85.34M
Operating Expenses USD 253.17M
Operating Profit USD -42.22M
Ordinary Share Capital USD 93K
Pre-Tax Profit USD -83.24M
Sales Revenues USD 308.01M
Selling and Administration Expenses USD 72.38M
Stock USD 266.01M
Trade Creditors USD 99.08M
Trade Debtors USD 112.74M

Gross Profit On Sales Change Date
Acasti Pharma USD 0 0 Mar/2022
Alaunos Therapeutics USD -1127000 1.11M Sep/2024
Aurora Cannabis CAD 27.95M 18.6M Jun/2025
Avita Medical AUD 16.13M 3.05M Dec/2024
Canopy Growth CAD 18.04M 6.06M Jun/2025
Cronos Group USD 14.5M 770K Jun/2025
Dianthus Therapeutics USD 193K 970K Jun/2025
Divis Laboratories Ltd 14.54B 1.5B Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
IQVIA Holdings USD 1.05B 251M Jun/2025
Knight Therapeutics CAD 45.02M 2.32M Sep/2024
Moderna USD 18M 1000K Jun/2025
Organigram Holdings CAD 26.15M 25.1M Jun/2025
Organon & Co USD 874M 33M Jun/2025
Revvity USD 392.56M 17.01M Jun/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 61.22M 1.51M Nov/2024
Viatris USD 1.33B 98.1M Jun/2025
Xeris Pharmaceuticals USD 59.64M 9.02M Jun/2025